LYTACs: Lysosome-Targeting Chimeras
Introduction
Classical PROTACs and molecular glues degrade intracellular proteins via the ubiquitin-proteasome system. But roughly 25–40% of the human proteome — secreted proteins, extracellular domains, and membrane-anchored receptors — lies beyond the reach of the proteasome. LYTACs (lysosome-targeting chimeras) address this gap by hijacking the cell's endolysosomal trafficking machinery to internalize and degrade extracellular and membrane-bound targets.
A LYTAC is a bifunctional molecule: one end binds the target protein (typically via an antibody or nanobody), while the other carries a synthetic glycan ligand that engages a cell-surface lysosomal-targeting receptor. Co-engagement of both triggers receptor-mediated endocytosis and delivery to the lysosome for degradation — entirely independent of E3 ligases and ubiquitination.
LYTAC Mechanism
LYTACs exploit two principal receptor pathways for lysosomal delivery, each with distinct tissue distribution and glycan ligand requirements.
Mannose-6-Phosphate Receptor (CI-M6PR)
The cation-independent mannose-6-phosphate receptor (~300 kDa) is ubiquitously expressed and normally shuttles M6P-tagged lysosomal enzymes from the Golgi to lysosomes. LYTACs co-opt this pathway by conjugating synthetic M6P glycopolypeptides to a target-binding antibody.
- Broadly expressed at the receptor level — but in-vivo LYTAC biodistribution is dominated by antibody PK and reticuloendothelial uptake; robust extra-hepatic degradation in vivo remains unproven
- Three M6P-binding domains (domains 3, 5, and 9) contribute to binding; domains 3 and 9 are high-affinity sites, domain 5 binds with lower affinity
- pH-dependent release: cargo released at endosomal pH (~5.5)
- Multivalent M6P glycopolypeptides achieve low-nM apparent KD via avidity (vs. ~10–20 μM for monovalent M6P)
Asialoglycoprotein Receptor (ASGPR)
ASGPR is a C-type lectin highly expressed on hepatocytes. It recognizes tri-GalNAc (N-acetylgalactosamine) clusters — the same targeting moiety used in GalNAc-siRNA therapeutics. ASGPR-based LYTACs enable liver-selective degradation of circulating proteins.
- Liver-selective expression — enables tissue-targeted degradation
- Calcium-dependent lectin — requires 2–5 mM CaCl₂ for binding
- Tri-GalNAc clusters bind ~1000× tighter than monovalent GalNAc
- Regeneration via EDTA chelation (strips Ca²⁺, releases ligand)
The LYTAC Degradation Cycle
Related Lysosomal Degrader Modalities
LYTACs are not the only approach to lysosomal degradation. Two related modalities take different routes to the same destination.
MoDE-As
Molecular Degraders of Extracellular proteins through the ASGPR. Fully synthetic, small-molecule bifunctional compounds — no antibody component. One moiety binds an extracellular target; the other is a GalNAc cluster engaging ASGPR on hepatocytes.
- Drug-like molecules, potentially orally bioavailable
- Liver-selective via ASGPR expression
- SPR characterization is analogous to PROTAC ternary assays, but cooperativity (α) is typically near 1 — unlike PROTACs, there is usually no direct receptor–target protein interface, so productive cooperativity is not expected
GlueTACs
Combine a target-binding nanobody with a cell-penetrating peptide (CPP) and a lysosome-sorting sequence (LSS). The defining "glue" feature is a covalent crosslink between the nanobody and its cell-surface target, typically via an unnatural amino acid (e.g., fluorosulfate-L-tyrosine, FSY). Unlike LYTACs, GlueTACs do not require a specific trafficking receptor — the LSS directly engages lysosomal sorting machinery.
- Receptor-independent lysosomal targeting
- SPR is simpler (binary nanobody–target kinetics only)
- Nanobody kinetics: faster kon and koff vs. IgG
Therapeutic Window & PK Considerations
Receptor expression maps and in-vitro tissue-culture degradation overstate what is clinically achievable. LYTAC pharmacology is governed less by the glycan–receptor affinity than by the PK and disposition of the conjugate as a whole.
- Antibody-dominated PK. Plasma half-life and biodistribution of antibody-LYTACs track the IgG, not the receptor. Large glycopolypeptide conjugates also see substantial liver/spleen reticuloendothelial uptake regardless of intended target tissue.
- Glycan stability. The M6P phosphate is enzymatically labile — serum and tissue phosphatases progressively strip M6P from the glycopolypeptide, eroding receptor engagement over the dosing interval. Phosphonate or non-hydrolyzable M6P mimetics are an active area of chemistry.
- Receptor sink. CI-M6PR also binds IGF-II (at domain 11) and is engaged by endogenous M6P-tagged hydrolases; ASGPR is a saturable hepatocyte pool. Both can buffer or compete with LYTAC dosing, particularly in IGF-II–rich compartments (serum, placenta).
- Immunogenicity. Multivalent glycopolypeptide–antibody conjugates are larger and more chemically heterogeneous than naked antibodies, raising the bar for ADA risk assessment.
- Clinical maturity. As of 2026, no LYTAC has entered registered clinical trials. The platform is preclinical; the GalNAc arm benefits from >15 years of ASGPR-targeted siRNA validation (givosiran, inclisiran), but extra-hepatic CI-M6PR LYTACs remain unproven in humans.
SPR/BLI Characterization
LYTAC characterization requires measuring three classes of interaction: glycan → receptor, antibody → target, and the bridging ternary complex.
1. Glycan–Receptor Binding Kinetics
The interaction between the synthetic glycan ligand and the trafficking receptor (CI-M6PR or ASGPR) is the defining measurement for LYTACs.
| Interaction | KD Range | ka (M⁻¹s⁻¹) | kd (s⁻¹) | Notes |
|---|---|---|---|---|
| Monovalent M6P → CI-M6PR | 10–20 μM | ~10³ M⁻¹s⁻¹ | ~10⁻² s⁻¹ | Weak, fast; steady-state fitting preferred due to rapid equilibration |
| M6P glycopolypeptide (multivalent) → CI-M6PR | 1–50 nM | 10⁴–10⁵ M⁻¹s⁻¹ | 10⁻⁴–10⁻³ s⁻¹ | Avidity-driven; apparent KD depends on valency |
| Monovalent GalNAc → ASGPR CRD | ~1 mM | 10³–10⁴ M⁻¹s⁻¹ | ~10⁻¹ s⁻¹ | Intrinsic single-CRD affinity; a tri-GalNAc that only engages one CRD behaves functionally as monovalent |
| Tri-GalNAc → ASGPR (trimer) | 1–50 nM | 10⁴–10⁵ M⁻¹s⁻¹ | 10⁻⁴–10⁻³ s⁻¹ | Avidity-enhanced with oligomeric receptor |
2. Antibody–Target Binding
The target-binding warhead (typically an antibody or nanobody) is characterized using standard protein–protein interaction SPR — this arm determines which extracellular protein is recruited for degradation.
Recommended Setup
- Capture antibody via anti-Fc or Protein A surface
- Flow target ectodomain as analyte
- Low capture density (~200–500 RU) for kinetics
- Multi-cycle kinetics with 5–7 concentrations
Expected Kinetics
- KD: 0.1–50 nM (typical antibody range)
- ka: 10⁵–10⁶ M⁻¹s⁻¹
- kd: 10⁻⁴–10⁻³ s⁻¹
- Standard 1:1 Langmuir fitting
3. Ternary Bridging Assay
The critical experiment confirming that a LYTAC can simultaneously engage both the trafficking receptor and the target protein. This is a sequential injection (bridging) assay.
Capture receptor on surface (e.g., biotinylated CI-M6PR on streptavidin chip / SA biosensor)
Inject LYTAC — observe association to receptor via the glycan moiety
Inject target protein (without regeneration) — additional mass gain confirms ternary complex formation
On BLI (Octet), this is a natural dip-and-read sequential binding assay. On SPR, use sequential multi-cycle injection with the second analyte injected during the dissociation phase of the first.
Experimental Design Considerations
Immobilization Challenges
CI-M6PR Ectodomain (~300 kDa)
Direct amine coupling gives high-density surfaces. For orientation control, use His-tag capture on NTA/anti-His surfaces. Target ~500–2000 RU for kinetic studies; ~5000–8000 RU for screening.
ASGPR
The functional receptor is a hetero-oligomer — approximately (H1)₂H2 or (H1)₃H2 — where H1 (ASGR1) and H2 (ASGR2) subunits assemble in a ~2:1 or 3:1 ratio. Immobilizing H1 monomer gives binary affinity but misses avidity. For avidity-relevant measurements, capture (H1)₂H2 heterotrimers or use cell-based BLI with ASGPR-expressing cells on Octet biosensors (whole-cell tethering).
Glycan Ligand Surfaces
Biotinylated M6P-glycopolypeptides on SA surfaces. Use planar surfaces (C1 chip, NTA without dextran) if non-specific binding is observed — polysaccharide-based ligands can stick to CM dextran on standard CM5 chips.
Avidity Effects with Multivalent M6P Glycans
Multivalent M6P glycopolypeptides are a defining feature of LYTACs — and the most common source of confusion in their SPR characterization. The apparent KD of a multivalent construct can be 100–1000× tighter than the intrinsic monovalent affinity, but this does not reflect true thermodynamic affinity.
KD ~10–20 μM — weak, fast on/off
Represents intrinsic single-site affinity. Use for mechanistic understanding.
Apparent KD ~1–50 nM — slow dissociation
Avidity-dominated. Relevant to functional potency; depends on valency.
Best Practice: Report both intrinsic (monovalent) and avidity-enhanced (multivalent) KD values. Use low-density receptor surfaces and monovalent analytes for intrinsic KD; use high-density surfaces intentionally when measuring functional avidity.
Buffer & Regeneration Conditions
| Parameter | CI-M6PR Assays | ASGPR Assays |
|---|---|---|
| Running Buffer | HBS-EP+ (pH 7.4), 10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.05% P20 | HBS-P+ with 2–5 mM CaCl₂ (no EDTA) |
| Regeneration | 10 mM glycine pH 2.0 (30 s pulses) | 10 mM EDTA chelation, then CaCl₂ re-equilibration |
| Critical Additive | — | Ca²⁺ is essential — omission is the most common cause of false-negative results |
Common Pitfalls & Solutions
| Pitfall | Description | Mitigation |
|---|---|---|
| Calcium Omission | ASGPR is a Ca²⁺-dependent lectin. No calcium = no binding. | Always include 2–5 mM CaCl₂ in running buffer for ASGPR assays. |
| Avidity Artifacts | Multivalent M6P on high-density receptor surfaces gives avidity-dominated kinetics that do not reflect intrinsic affinity. | Use low-density surfaces and monovalent analytes for intrinsic KD. Use high-density surfaces intentionally for functional avidity. |
| M6P Heterogeneity | Synthetic M6P glycopolypeptides often have polydisperse valency, yielding ambiguous kinetic fits. | Characterize valency distribution (SEC-MALS, MALDI) before SPR. |
| CI-M6PR Truncation | CI-M6PR has three M6P-binding domains (3, 5, and 9). Domains 3 and 9 are the high-affinity sites; domain 5 binds with lower affinity. Truncated constructs may underestimate affinity. | Use full ectodomain when possible. Report which domains are included. |
| Non-Specific Binding | Glycan ligands can stick to CM dextran on standard CM5 chips. | Use planar surfaces (C1 chip, NTA without dextran) if non-specific binding is observed. |
Key Differences from Proteasomal TPD
Lysosomal degradation via LYTACs represents a fundamentally different biology from PROTAC/molecular glue-mediated proteasomal degradation, and this has direct implications for kinetic characterization.
| Feature | PROTACs / Glues | LYTACs |
|---|---|---|
| Target Location | Intracellular | Extracellular / membrane |
| Degradation Pathway | Ubiquitin-proteasome system | Endo-lysosomal pathway |
| E3 Ligase Required? | Yes (VHL, CRBN, etc.) | No — uses trafficking receptors |
| Key SPR Interaction | PROTAC–E3 ternary complex stability | Glycan–receptor affinity & avidity |
| Cooperativity (α) | Central metric — drives selectivity | Measurable but less predictive of efficacy |
| Residence Time | Longer t1/2 → more ubiquitination → better degradation | Internalization rate may matter more than complex stability |
| Tissue Selectivity | Determined by target expression | Also determined by receptor choice (CI-M6PR broadly expressed but in-vivo biodistribution antibody/RE-dominated; ASGPR = liver) |
Key Insight: For PROTACs, ternary complex residence time is the best biophysical predictor of degradation efficiency. For LYTACs, the relationship is less direct — lysosomal trafficking kinetics (internalization rate, endosomal sorting efficiency) may matter more than the absolute stability of the receptor–LYTAC–target complex. SPR data informs affinity optimization, but functional degradation assays remain essential for efficacy prediction.
Data Interpretation
Report Both KD Values
Always report both intrinsic (monovalent) and avidity-enhanced (multivalent) KD values. Both are biologically relevant: intrinsic affinity informs medicinal chemistry optimization; avidity reflects functional potency.
Ternary Bridging Quantification
For bridging assays, report the additional binding response (ΔRU or Δnm shift) as evidence of ternary complex formation, along with kinetics of the second binding event. Cooperativity factor α = KD(binary) / KD(ternary context).
pH-Dependent Release
CI-M6PR releases cargo at endosomal pH (~5.5). Running SPR at both pH 7.4 and pH 5.5 can confirm that the LYTAC construct will release its target in the endosome, enabling receptor recycling for additional degradation cycles.
Key References
Banik SM, Pedram K, Wisnovsky S, Ahn G, Riley NM, Bertozzi CR. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature. 2020;584(7820):291–297.
Ahn G, Banik SM, Miller CL, Riley NM, Cochran JR, Bertozzi CR. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation. Nat Chem Biol. 2021;17(9):937–946.
Caianiello DF, Zhang M, Ray JD, Harding RA, Spiegel DA. Bifunctional small molecules that mediate the degradation of extracellular proteins. Nat Chem Biol. 2021;17(9):947–953.
Zhang H, Han Y, Yang Y, Lin F, Li K, Kong L, et al. Covalently engineered nanobody chimeras for targeted membrane protein degradation. J Am Chem Soc. 2021;143(40):16377–16382. (GlueTACs)